Consolidated Balance Sheets $ in Thousands	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Current assets:
Cash and cash equivalents	$ 7,901	$ 6,602
Restricted cash		4
Prepaid expenses and other current assets	283	177
Total current assets	8,184	6,783
Property, equipment and leasehold improvements, net	83	73
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,000	1,211
Prepaid clinical trial expenses	1,122	1,122
Other assets	13	26
Total assets	10,512	9,325
Current liabilities:
Accounts payable	587	942
Operating lease liabilities	318	294
Accrued expenses	962	1,427
Total current liabilities	1,867	2,663
Other liabilities	59	59
Operating lease liabilities - non current	779	1,020
Total liabilities	2,705	3,742
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 50,000,000 shares; 4,882,420 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at September 30, 2020; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019	2	2
Additional paid-in capital	233,847	224,741
Accumulated deficit	(226,042)	(219,160)
Total stockholders’ equity	7,807	5,583
Total liabilities and stockholders’ equity	$ 10,512	$ 9,325